Biotech IPO market rebounds as investor interest in GLP-1 drugs and diagnostic innovation challenges AI's dominance in venture funding

Kailera and Alamar are leading a resurgence in biotech IPOs after a period of investor drought in the life sciences sector

Strong market demand for GLP-1 drugs is driving renewed investor confidence in biotech companies

Next-generation diagnostic testing platforms are attracting significant capital despite AI companies capturing the majority of venture dollars

The shift signals a diversification of venture investment away from AI-focused companies back into healthcare innovation